TYVASO DPI IS NOW APPROVED

Learn more
Skip to main content

FOR US HEALTHCARE PROFESSIONALS ONLY

For the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability.

FOR US HEALTHCARE PROFESSIONALS ONLY

SELECT INDICATION
Search Button
Skip to main content
FOR US HEALTHCARE PROFESSIONALS ONLY
logo
logo
SELECT INDICATION

ABOUT PH-ILD

WHAT IS TYVASO?

CLINICAL STUDIES

STARTING TYVASO

RESOURCES & SUPPORT

BENEFITS OF REACHING TARGET DOSE

Help your patients get the most out of TYVASO by achieving the target maintenance dose1

6MWD

Patients receiving a higher dose of TYVASO achieved a 67% greater improvement in 6MWD at 16 weeks1

Patients receiving a higher dose of TYVASO achieved nearly double the improvement in 6MWD at 16 weeksPatients receiving a higher dose of TYVASO achieved nearly double the improvement in 6MWD at 16 weeks

Hodges-Lehmann placebo-corrected median difference.

In the MMRM analysis, patients achieving 10-12 breaths had nearly double the improvement in 6MWD at 16 weeks. Change in 6MWD by dose was a prespecified subgroup analysis.2

Clinical Worsening

Fewer patients in the higher-dose group experienced a clinical worsening event3

The clinical worsening data is a post hoc analysis of data from a prespecified efficacy endpoint.The clinical worsening data is a post hoc analysis of data from a prespecified efficacy endpoint.

Percentage of patients experiencing an event.

The clinical worsening data is a post hoc analysis of data from a prespecified efficacy endpoint. Interpret with appropriate caution.

Our TYVASO Nebulizer Treatment Tracker can help your patients stay on track with their treatment sessions.

Setting your patients up for success

1

Set realistic expectations

  • As the patient titrates to target maintenance dose, they may not see immediate clinical improvements4

Explain importance of reaching target maintenance dose to realize full benefits1

2

Prepare for common AEs

  • Review AEs (eg, cough, headache, and throat irritation) and why they may occur5
  • Give patients specific instructions to proactively manage any AEs that occur
  • Complete AE Management section on the Referral Form

Stress that they should not stop treatment without consulting you

See AE Management Approaches

3

Ensure patients understand the dosing plan

  • With the TYVASO nebulizer, target maintenance dose can be achieved by starting with 3 breaths per session at week 1 and increasing by 1 breath per week until reaching 9-12 breaths per session1,6
  • With TYVASO DPI, target maintenance dose can be achieved by starting with 16 mcg (1 cartridge) and increasing by 16 mcg at 1- to 2-week intervals to a target maintenance dose of 48 mcg to 64 mcg per treatment session7
  • Once the target maintenance dose is achieved, the patient should maintain that dose with each treatment session, as tolerated

Emphasize importance of completing all 4 daily treatment sessions

6MWD=6-minute walk distance; AE=adverse event; MMRM=mixed-effect model repeat measurement.

View AE management techniques

The information contained in this section of the site is clinical in nature and specifically created for healthcare professionals. If you are not a US healthcare professional, please click CLOSE to return to the consumer section of the site.

CLOSE

Yes, I am a US healthcare professional and would like to continue.